Genomic Interrogation of Secondary-Type Acute Myeloid Leukemia: Response and Outcomes to Contemporary Therapies,” published in the February 2025 issue of American Journal of Hematology by Senapati et ...
(AML) patients across both original and expansion cohorts remain in complete remission (CR), with a median follow-up of 20.1 ...
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.3cY8rBmp.js ...
IN8bio has announced encouraging new clinical data from its ongoing Phase I trial of INB-100, an allogeneic gamma-delta T ...
The Loch Raven Athletic Hall of Fame celebrates 10 new inductees in its first class since before the pandemic.
Holdings provides an update from the Company’s ongoing Phase 1/1b clinical trial of BP1001-A in solid tumor patients and ...
Moleculin Biotech (MBRX) has received FDA feedback and guidance on its IND amendment that has allowed a reduction in the size of its Phase 3 ...
The Standard-Times on MSN2d
New Bedford family of toddler fighting leukemia gets support from Cops for Kids with CancerCops for Kids with Cancer seeks to remove the financial burden for families impacted by a cancer diagnosis. This week they ...
(AML) patients across both original and expansion cohorts remain in complete remission (CR), with a median follow-up of 20.1 months AML patients treated demonstrated one-year ...
February 14, 2025 - IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, yesterday presented ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback